Podcast
MSL Talk: Tom Caravela, Sarah Snyder
HOLD MY BEER… I’m Going to be an MSL
Summary
In this episode, Lana Lucidi shares her journey from early career roles to becoming a Medical Science Liaison. She delves into her transition process, highlighting the importance of mentorship, networking, and leveraging transferable skills. Lana addresses common challenges faced when pursuing an MSL role, particularly navigating job descriptions and targeting the right companies. She offers valuable advice for aspiring MSLs, emphasizing the significance of building expertise and confidence, especially when engaging with Key Opinion Leaders (KOLs). The episode concludes with reflections on the MSL role, the impact of the MSL Talk podcast, and words of encouragement for those on the MSL path.
My guest this week is Lana Luccitti, Medical Science Liaison with Topcon Health who discusses how it is possible to land an MSL role without a Doctorate.
Lana shares…
👉 What made her want to be an MSL
👉 The first thing she did in her MSL Search
👉 The frustrations she had along the way
👉 What helped her stand out from others
👉 Most important advice she can offer
Medical Science Liaison, career transition, mentorship, networking, transferable skills
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Sarah Snyder
Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Social Media Listening Evolved
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary